Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Compass Therapeutics
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
Northwell Health
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
University of Texas Southwestern Medical Center
Bristol-Myers Squibb
National Cancer Institute (NCI)
Georgetown University
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
University of Maryland, Baltimore
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
Eli Lilly and Company
Roswell Park Cancer Institute
Vanderbilt University Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
National Cancer Institute, Egypt
M.D. Anderson Cancer Center
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Taichung Veterans General Hospital
Institut Claudius Regaud
M.D. Anderson Cancer Center